Table 5.
Comparison of urinary biomarkers and blood pressures in patients on bevacizumab and patients on small molecule VEGF inhibitors, with medians (IQR) and p values by Wilcoxon test for comparisons
| Biomarker or clinical variable | Bevacizumab (N=11) | Small molecule VEGF inhibitors (N=29) | P value |
|---|---|---|---|
| NOx /Cr, umol/mg | 0.67 (0.45–1.41) | 0.36 (0.26–0.58) | 0.01 |
| cGMP/Cr, pmol/ug | 0.47 (0.19–0.77) | 0.25 (0.22–0.36) | 0.28 |
| PGE2/Cr, pg/ug | 1.50 (0.80–2.54) | 1.08 (0.78–1.82) | 0.48 |
| cAMP/Cr, pmol/ug | 4.71 (4.27–6.49) | 5.09 (4.68–7.43) | 0.30 |
| 6-keto PGF 1α/Cr, pg/ug | 1.26 (0.94–2.22) | 1.03 (0.85–1.31) | 0.07 |
| ACR, mg/g | 18.3 (7.9–607.9) | 18.5 (0–232.3) | 0.55 |
| Number of blood pressure medications | 2 (0–3) | 1 (0–2) | 0.82 |
| Days of medication prior to collection | 140 (80–245) | 70 (21–168) | 0.09 |
*
Mean (SD)
VEGF denotes vascular endothelial growth factor; IQR, interquartile range; NOx, nitric oxide; Cr, creatinine; cGMP, cyclic GMP; PGE2, prostaglandin E2; cAMP, cyclic AMP; ACR, albumin:creatinine ratio